Skip to main content
    E

    Evolent Health Inc (EVH)

    Official site

    HEALTHCARE • HEALTH INFORMATION SERVICES • NYSE

    $4.83
    -0.07 (-1.53%)

    Market Cap: $554.22M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Evolent Health Inc (EVH) Earnings: Report Dates and Results

    Updated Nov 5, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Evolent Health (EVH) is expected to report earnings on Feb 22, 2027. In the quarter ended Sep 30, 2026, Evolent Health reported EPS of -$0.04, above the -$0.05 estimate. It beat the EPS estimate in 2 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    56%(22/39)
    Avg Surprise
    +29.29%
    Streak
    1 Q

    Upcoming Estimates

    Reports Feb 22, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus$0.16
    Range$0.07 - $0.22
    16 analysts
    Revenue Consensus
    $767.96M
    Range$702.66M - $827.74M
    16 analysts
    Reports May 5, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus$0.07
    Range$0.01 - $0.13
    6 analysts
    EPS Revisions
    1
    2
    30d
    EPS Estimate DriftChange to current
    90d ago$0.06+10.2%
    60d ago$0.07-5.1%
    30d ago$0.07-5.1%
    7d ago$0.07-5.1%
    Current$0.07
    Revenue Consensus
    $795.70M
    Range$688.15M - $893.03M
    10 analysts

    Next Report

    EVH has an expected report date of Feb 22, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 100.0% above the $0.08 reported for the quarter ended Dec 31, 2025.

    EVH Earnings Call

    The latest EVH earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 39 quarters below that had an estimate, EVH beat 22, missed 13 and matched 4. Revenue for the quarter ended Sep 30, 2026 was $725.37M, up 51.3% from $479.53M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.04-$0.05N/A+20.00%Beat-180.0%95 up, 3 downNov 5, 2026$725.37M
    Jun 30, 2026-$0.11-$0.10N/A-10.00%MissN/A100 up, 1 downAug 6, 2026$652.52M
    Mar 31, 2026-$0.02$0.05N/A-136.83%Miss-133.3%100 up, 4 downMay 7, 2026$496.25M
    Dec 31, 2025$0.08$0.05-$0.05 - $0.09+60.00%BeatN/A120 up, 1 downFeb 24, 2026$468.72M
    Sep 30, 2025$0.05$0.10$0.05 - $0.20-50.00%Miss+25.0%110 up, 3 downNov 6, 2025$479.53M
    Jun 30, 2025-$0.17$0.08$0.05 - $0.15-312.50%Miss-156.7%100 up, 0 downAug 7, 2025$444.33M
    Mar 31, 2025$0.06$0.10$0.03 - $0.15-40.00%Miss-82.4%90 up, 7 downMay 8, 2025$483.65M
    Dec 31, 2024-$0.02$0.01-$0.13 - $0.09-260.00%Miss-108.7%121 up, 9 downFeb 20, 2025$646.54M
    Sep 30, 2024$0.04$0.34$0.22 - $0.41-88.24%Miss-86.7%120 up, 1 downNov 7, 2024$621.40M
    Jun 30, 2024$0.30$0.25$0.15 - $0.32+20.00%Beat+114.3%110 up, 1 downAug 8, 2024$647.14M
    Mar 31, 2024$0.34$0.30$0.10 - $0.34+13.33%Beat+61.9%112 up, 0 downMay 9, 2024$639.65M
    Dec 31, 2023$0.23$0.15$0.01 - $0.30+53.33%Beat+130.0%90 up, 0 downFeb 22, 2024$556.05M
    Sep 30, 2023$0.30$0.10-$0.14 - $0.16+200.00%Beat-49.2%70 up, 0 downNov 2, 2023$511.01M
    Jun 30, 2023$0.14$0.15-$0.08 - $0.19-6.67%Miss+40.0%70 up, 0 downAug 2, 2023$469.14M
    Mar 31, 2023$0.21$0.19$0.09 - $0.39+10.53%Beat+75.0%81 up, 0 downMay 3, 2023$427.69M
    Dec 31, 2022$0.10$0.16$0.05 - $0.56-37.50%Miss+25.0%71 up, 0 downFeb 22, 2023$382.43M
    Sep 30, 2022$0.59$0.10$0.06 - $0.24+490.00%BeatN/A70 up, 0 downNov 2, 2022$352.58M
    Jun 30, 2022$0.10$0.05-$0.01 - $0.09+100.00%BeatN/A70 up, 0 downAug 2, 2022$319.94M
    Mar 31, 2022$0.12$0.00-$0.11 - $0.05N/AN/AN/A51 up, 0 downMay 4, 2022$297.06M
    Dec 31, 2021$0.08$0.01-$0.08 - $0.09+700.00%BeatN/A61 up, 0 downFeb 23, 2022$248.36M
    Sep 30, 2021-$0.03-$0.03-$0.12 - $0.030.00%In lineN/A7N/ANov 3, 2021$222.47M
    Jun 30, 2021-$0.02-$0.03-$0.12 - $0.02+33.33%BeatN/A5N/AAug 4, 2021$222.06M
    Mar 31, 2021-$0.01-$0.07-$0.15 - $0.03+85.71%BeatN/A8N/AMay 5, 2021$215.07M
    Dec 31, 2020-$0.01-$0.05-$0.09 - -$0.01+80.00%BeatN/A8N/AFeb 25, 2021$246.54M
    Sep 30, 2020-$0.03-$0.05-$0.11 - $0.02+40.00%BeatN/A10N/ANov 5, 2020$239.57M
    Jun 30, 2020-$0.03-$0.10-$0.19 - -$0.03+70.00%BeatN/A11N/AAug 4, 2020$217.30M
    Mar 31, 2020-$0.14-$0.13-$0.22 - -$0.10-7.69%MissN/A9N/AMay 7, 2020$221.23M
    Dec 31, 2019-$0.07-$0.04-$0.08 - $0.01-75.00%MissN/A10N/AFeb 25, 2020N/A
    Sep 30, 2019-$0.09-$0.12-$0.23 - -$0.05+25.00%BeatN/A12N/ANov 5, 2019$220.14M
    Jun 30, 2019-$0.26-$0.23-$0.34 - -$0.12-13.04%MissN/A13N/AAug 6, 2019$383.92M
    Mar 31, 2019-$0.31-$0.33-$0.57 - -$0.18+6.06%Beat-1650.0%14N/AMay 7, 2019$197.76M
    Dec 31, 2018-$0.07-$0.04-$0.08 - $0.01-75.00%MissN/A14N/AFeb 26, 2019$193.10M
    Sep 30, 2018-$0.04-$0.04N/A0.00%In lineN/AN/AN/ANov 6, 2018$149.95M
    Jun 30, 2018-$0.03-$0.04-$0.07 - -$0.01+25.00%BeatN/A15N/AAug 7, 2018$144.30M
    Mar 31, 2018$0.02-$0.04-$0.07 - -$0.02+150.00%BeatN/A12N/AMay 9, 2018$139.71M
    Dec 31, 2017-$0.04-$0.04-$0.07 - -$0.020.00%In lineN/A14N/AFeb 27, 2018$113.73M
    Sep 30, 2017-$0.04-$0.08-$0.12 - -$0.07+50.00%BeatN/A13N/ANov 2, 2017$107.91M
    Jun 30, 2017-$0.13-$0.13-$0.16 - -$0.100.00%In lineN/A11N/AAug 7, 2017$107.07M
    Mar 31, 2017-$0.14-$0.16N/A+12.50%BeatN/AN/AN/AMay 9, 2017$106.24M
    Dec 31, 2016-$0.18-$0.20N/A+10.00%BeatN/AN/AN/AFeb 28, 2017$88.01M
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was $0.02, down 97.0% from the year before. It was -$0.57 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025$0.02-97.0%
    Dec 31, 2024$0.66-25.0%
    Dec 31, 2023$0.88N/A
    Dec 31, 2022$0.91+4450.0%
    Dec 31, 2021$0.02N/A
    Dec 31, 2020-$0.21N/A
    Dec 31, 2019-$0.73N/A
    Dec 31, 2018-$0.12N/A
    Dec 31, 2017-$0.35N/A
    Dec 31, 2016-$0.57N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 6,100 words across 12 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20266,07112
    2026Q2Jun 30, 20266,53314
    2026Q1Mar 31, 20265,38712
    2025Q4Dec 31, 20258,92917
    2025Q3Sep 30, 20255,77813
    2025Q2Jun 30, 20255,23611
    2025Q1Mar 31, 20256,40614
    2024Q4Dec 31, 20247,96916

    2026Q3 Earnings Call

    Opening remarks

    Seth Blackley CEO Good morning, and thank you for joining us. Today, we reported third quarter results that we believe reflect strong continued progress against the priorities we laid out at the beginning of the year. We grew our Performance Suite business, improved our care margins, and stayed disciplined on operating expenses, all while continuing to innovate at the core of our business. For the quarter, Evolent reported total revenue of $725 million, up 11% versus Q2, and Adjusted EBITDA of $34 million, up approximately 22% sequentially. Our medical expense ratio, or MER, was 93%, compared with 95% in the second quarter. The improvement reflects favorable in-year claims development and contractual adjustments. Mario will provide more details on those drivers in a few moments. Based on our results through the first nine months and our current view of the fourth quarter, we are reiterating our full-year revenue guidance of $2.6 billion-$2.7 billion and raising our Adjusted EBITDA guidance to $130 million-$135 million. Before turning it over to Mario, I want to talk you through four topics. One, the strength of our customer relationships and the related growth. Two, updates from our 2026 Performance Suite launches. Three, how we are both broadening our product footprint and accelerating our AI innovation. And fourth, our balance sheet. Let's start with the initial topic of customer relationships and growth. As we've discussed on previous calls, renewals and expansions are at the heart of our growth story. I'd like to share several proof points of that today. First, we renewed our largest Surgical Management customer contract for an additional four years. You will recall, Surgical Management is the IPG business we acquired in 2022. We view this as more than a renewal. It's a longstanding partner committing to a multi-year deal, demonstrating that our model works and that they want us at their side managing musculoskeletal and cardiovascular care for the long run. Second, an existing client signed an agreement to expand their oncology offering, covering several additional states and approximately 1 million commercial lives, with go-live expected January 1, 2027. This is our first expansion with this client, and we believe it demonstrates the trust they've placed in us, but also something more strategically important. It's significant to note that this expansion will also include Member Navigation across all existing and new lives, meaning we're not just growing with the client, we're broadening the footprint by adding our member-facing solution. This is exactly the kind of product breadth expansion that defines our next phase of growth, taking a client under contract with one solution and giving them a reason to trust us with additional solutions.

    Frequently Asked Questions About EVH

    When is Evolent Health's next earnings date?

    Evolent Health's next earnings report is expected for Feb 22, 2027.

    Did EVH beat earnings estimates last quarter?

    Yes. Evolent Health reported EPS of -$0.04 for the quarter ended Sep 30, 2026, above the -$0.05 estimate, a 20.00% surprise.

    What EPS do analysts expect from EVH next quarter?

    The consensus EPS estimate for Evolent Health for the quarter ending Dec 31, 2026 is $0.16 from 16 analysts, with estimates from $0.07 to $0.22.

    How often does EVH beat earnings estimates?

    Evolent Health beat the EPS estimate in 2 of the last 8 quarters, with an average surprise of -91.17%.